BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 16462581)

  • 1. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
    Yancey A; Harris MS; Egbelakin A; Gilbert J; Pisoni DB; Renbarger J
    Pediatr Blood Cancer; 2012 Jul; 59(1):144-8. PubMed ID: 22431292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
    Moke DJ; Luo C; Millstein J; Knight KR; Rassekh SR; Brooks B; Ross CJD; Wright M; Mena V; Rushing T; Esbenshade AJ; Carleton BC; Orgel E
    Lancet Child Adolesc Health; 2021 Apr; 5(4):274-283. PubMed ID: 33581749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.
    Landier W; Knight K; Wong FL; Lee J; Thomas O; Kim H; Kreissman SG; Schmidt ML; Chen L; London WB; Gurney JG; Bhatia S
    J Clin Oncol; 2014 Feb; 32(6):527-34. PubMed ID: 24419114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group.
    Grewal S; Merchant T; Reymond R; McInerney M; Hodge C; Shearer P
    Pediatrics; 2010 Apr; 125(4):e938-50. PubMed ID: 20194279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report on hearing loss in oncology.
    Schultz C; Goffi-Gomez MV; Liberman PH; Carvalho AL
    Braz J Otorhinolaryngol; 2009; 75(5):634-41. PubMed ID: 19893928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin ototoxicity in children: implications for primary care providers.
    Helt-Cameron J; Allen PJ
    Pediatr Nurs; 2009; 35(2):121-7. PubMed ID: 19472677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin: continuous versus bolus.
    Gratton MA; Smyth BJ
    J Pediatr Hematol Oncol; 2006 Feb; 28(2):60-1. PubMed ID: 16462573
    [No Abstract]   [Full Text] [Related]  

  • 8. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
    Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
    Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatinum ototoxicity in children, long-term follow up.
    Al-Khatib T; Cohen N; Carret AS; Daniel S
    Int J Pediatr Otorhinolaryngol; 2010 Aug; 74(8):913-9. PubMed ID: 20846503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors.
    Gupta AA; Capra M; Papaioannou V; Hall G; Maze R; Dix D; Weitzman S
    J Pediatr Hematol Oncol; 2006 Feb; 28(2):91-4. PubMed ID: 16462581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery from cisplatin-induced ototoxicity: a case report and review.
    Truong MT; Winzelberg J; Chang KW
    Int J Pediatr Otorhinolaryngol; 2007 Oct; 71(10):1631-8. PubMed ID: 17706797
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.